Rybelsus on TikTok: What oral semaglutide videos get wrong

What did @ximenapharm.com actually say?

Honestly? It's hard to tell. The transcript appears to be a garbled machine translation from Romanian, and what comes through in English is largely incoherent. References to "federal government," "losing lives," and "the EU and the UN" bear no recognizable connection to Rybelsus (oral semaglutide) or type 2 diabetes management. The caption promises advice for someone on Rybelsus treatment, but the transcript delivers nothing clinically coherent.

This matters because the video has 103,800 views. People managing type 2 diabetes or using oral semaglutide for weight management may be watching this expecting real guidance. When a pharmacist-branded account posts under hashtags like #diabetes and #medicine, viewers reasonably expect medical information. What they appear to have gotten here is a translation artifact that communicates nothing verifiable about the drug.

Does the science back this up?

There is no identifiable scientific claim in this transcript to evaluate. That is not a technicality, it is a problem. Rybelsus (semaglutide 3 mg, 7 mg, 14 mg oral tablets) has a well-established evidence base that was simply not used here.

The PIONEER trial series, particularly PIONEER 1 through 8 (Aroda et al., 2019, Diabetes Care; Davies et al., 2019, JAMA), demonstrated meaningful HbA1c reductions with oral semaglutide across diverse patient populations. PIONEER 6 (Husain et al., 2019, New England Journal of Medicine) showed non-inferior cardiovascular outcomes versus placebo in high-risk patients. None of this was referenced. The video also missed what patients actually need to know: Rybelsus must be taken on an empty stomach with no more than 4 oz of water, at least 30 minutes before eating, because food and fluid significantly reduce oral bioavailability. That is a real, consequential clinical fact. It was not mentioned.

What did they get wrong (or right)?

Getting something wrong requires making a claim. Getting something right requires the same. This transcript does neither in any evaluable way. The translation failure is so complete that no specific Rybelsus claims, accurate or inaccurate, can be extracted and assessed.

What we can say is that the framing is misleading by omission. A video titled as Rybelsus advice, posted by an account presenting as a pharmaceutical professional, should at minimum address absorption requirements, common gastrointestinal side effects (nausea affects roughly 15-20% of users, per the PIONEER data), and the drug's mechanism as a GLP-1 receptor agonist. None of these appear. The account gets no credit for accuracy because there is no accuracy to credit. It also earns no specific rebuttal because there are no specific claims to rebut. The problem here is the absence of substance, not the presence of error.

What should you actually know?

If you are taking Rybelsus, here is what the evidence actually supports. First, timing is everything with this drug. Oral semaglutide has poor bioavailability under normal conditions. The PIONEER pharmacokinetic studies showed that taking it with food or more than 4 oz of water can reduce absorption by up to 50%. This is not a minor detail.

Second, GLP-1 receptor agonists like semaglutide work by stimulating insulin secretion in a glucose-dependent manner, slowing gastric emptying, and reducing appetite signaling in the hypothalamus. Wilding et al. (2021, New England Journal of Medicine) showed the injectable version producing significant weight loss, but oral semaglutide at approved doses is primarily a glucose-lowering agent, not a weight loss drug at the doses currently approved in most markets.

Third, nausea and vomiting are real and common side effects, particularly at initiation. Dose escalation protocols exist for a reason. Any video giving Rybelsus advice without mentioning this is leaving out something patients will likely experience.

• Take Rybelsus on an empty stomach, 30+ minutes before food or other medications
• Use no more than 4 oz (120 mL) of plain water when taking the tablet
• GI side effects are common at initiation and typically improve after 4-8 weeks
• Rybelsus is approved for type 2 diabetes, not as a standalone weight loss treatment in most markets
• Do not substitute compounded oral semaglutide for Rybelsus without medical supervision